Related Experiment Video
Updated: Jul 16, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
[A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib]
Koichi Imai1, Junichi Ashitani, Shigehisa Yanagi
1Third Department of Internal Medicine, Miyazaki Medical College.
Abstract:
A 74-year-old smoking man was admitted because of lung cancer with metastatic brain tumor. Examinations for lung cancer and brain tumor showed adenocarcinoma (clinical stage IV). Four courses of chemotherapy were not effective. Administration of gefitinib started from June 2003, but was halted after only two months because of skin rash. Lung tumor disappeared on chest computerized tomography in January 2004 and no recurrence has been detected as of March 2006. This is a rare male super-responder to gefitinib.
